Enanta Pharma Q4 EPS $(1.33) Vs. $(1.27) Last Year, Sales $18.93M Beat $17.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Enanta Pharmaceuticals reported a Q4 EPS loss of $(1.33), a 4.72% increase in loss compared to $(1.27) last year. However, their sales of $18.93M exceeded the $17.50M estimate, despite being a 6.83% decrease from the previous year's $20.32M.
November 20, 2023 | 9:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Enanta Pharma's Q4 EPS loss widened to $(1.33) from $(1.27) YOY, but sales of $18.93M beat estimates and may soften the negative impact on the stock.
The increased EPS loss is negative for investor sentiment, but the sales beat could indicate better-than-expected revenue performance, which might counterbalance the negative EPS impact in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100